CYDY notes from the July 22, 2021 cc with some approximate

New Post Public Reply Private Reply Replies (3) Message Board
grow
2,122
CYDY notes from the July 22, 2021 cc with some approximate timings
NOT A TRANSCRIPT
Some points are highlighted, but all could be.



Cancer

1. mTNBC patients were mostly compassionate use. Will be talking with FDA about the path forward. This was trial closing data from P2. Hopefully Phase 3 or BTD to follow. Basket trial will follow same path.

2. Testimonials

3. MOA’s

4. 13:00- 16.44 One BTD (break through designation) for an indication in an annual $1B sales market can mean $8.3B. In other words, $8.3B for each cancer indication. It can also reduce time to approval by 2 ½ - 3 ½ years. There are at least 23 cancers that CYDY is looking at.

5. Right to try for the TNBC & cancer basket trials patients after the trial

6. 18:00 longest eIND patient



Longhaulers
(did not take notes in this segment)



Brazil

7. 33:40 2X a week (M & Th) we meet with the whole team at Albert Einstein research Group & Biomm

8. After almost 2 months of back and forth, gave them all the data they requested, we now have a solid CRO in Brazil for any study. Much more cost effective and with a good reputation. Just published in NEJM. All of the trial sites are ready to go, ready to inject.

9. Will be starting HIV prep study as well

10. 316 critical patients for Covid19 trial

11. 612 severe (“moderate” in Brazil defined terms) or Covid19 trial

12. Will look at Interim results at 40 patients

13. Will be a bonus to do patient enrollment in a very expedited way.

14. Have given ANVISA final comments and we are waiting any day for
greenlight


15. About 20 people or so on these team meetings

16. Scott Kelly- Biomm is a fantastic partner and we can get studies done more quickly with less expense.

17. Chris Recknor- They are outstanding and they have done 7 prior Covid studies.

18. 37:14 “A lot of the work we’ve done through this whole process in Brazil in terms of CMC and non-clinical has really put us in a fantastic position for submitting all throughout the world as well as all other indications. It’s really now we need to show efficacy in these indications and we have the ability to move forward very very quickly which most people do not have.”

19. 38:06 Philippines no news. No new PO yet. Covid is getting worse there.

20. 38:35 India cases went down but they are now asking about longhaulers


HIV BLA

21. 39:10 Wanted to work on biggest issue for FDA first, receptor occupancy assay.

22. 41:58 “Submitted on our draft to them, our plan for receptor occupancy, and they agreed, and we are proceeding. We’re thrilled. This is one huge obstacle that we now have overcome.”

23. 42:15 “We’ve always had the CMC portion dialed down, the issue has been the dose justification, and it’s complicated with the two different studies. Like you said the P value is significant, CD02 works, .032 significance. So really needed to get the dose justification in and we corresponded with the FDA. They wanted us to submit a draft dose justification and that’s what we’ve done, and we’re waiting for word back from them. This doesn’t change our October deadline. We have everything still in play for that. But I think getting the first hardest part that’s always been the stumbling block out of the way first , is the best thing, and we’re able to go forward. So we’re expecting to hear back from the FDA and when we get a greenlight on that, or we have to modify things will do so, but we’ll have the hardest part taken care of and behind us.”

24. Also, from later in the conference call
46.45 “We are going to put in the public domain what the FDA said about the previous receptor occupancy test that we submitted to them”



NASH

25. 43.35 NASH takes a long time to enroll, and many trials can take years. We believe this is the fastest NASH trial ever.

26. 60 current patients (700mg) have already completed the enrollment. Dr. Recknor wants 30 additional patients at 350mg. CEO is tempted to stop the trial at this current enrollment level and read data to ask FDA for P3. Some possibility with Brazil as well.

27. 46:05 “We should be getting a fill of the study of those 30 patients within the next 30 to 45 days and with that we will have more results of what 350mg looks like but also in combination with all these biomarkers that are immensely helping us.”



Biomarker Diagnostic Test Laboratory

28. 45:29 “We are developing a central repository for all of our biomarkers of which we can then learn from one indication to the next”

29. 46.37 Biomarker Diagnostic Test Laboratory & biomarker diagnostic test in development. It will make it easier for practitioners.



Patents

30. 49:00 Patent protection is growing rapidly. We are aware that patents were put on our products and we are pursuing that aggressively. We are patenting quite a bit of stuff.

31. 49:38 People working for the company may be on a patent, but it is assigned to the company. There are NDA’s in place where any work done for the company results in patent assignment to the company not worker or contractor.



Publishing & Presenting

32. TNBC P1b/2 data expected to be presented at conference by end of 2021

33. Longhaulers data needs to be published immediately

34. HIV BLA is clearer, so now is an opportune time for HIV publication, however the priority may be longhaulers, then HIV or CD10&12



Dosages

35. 57:35
dosages: 350mg 525mg, 700mg,
half life: IV 4 days, subQ injection 10 days
absorption: IV 1 hr, subQ injection 2 days

36. 59:00 Different indications may need different dosages. Biomarker attention is needed. Versatility in commercialization dosage is an advantage.

37. 1:01:05 concentrated leronlimab, every 3 months vs weekly. Encouraging work is ongoing.



Partners

38. 1:02:00 Have partners in Philippines, Brazil and India. Looking at potential partnerships in the USA and it’s getting even more interesting.




SOME RELATED LINKS

2021.07.22 CYDY Conference Call
https://www.cytodyn.com/newsroom/press-releas...sults-from


2021.07.22 Investor presentation
https://www.sec.gov/Archives/edgar/data/00011...dex992.htm


2021.07.19 Triple Negative Breast Cancer study preliminary results phase 1b portion of trial
https://www.cytodyn.com/newsroom/press-releas...m-30-mtnbc


2021.07.06 CCytoDyn Granted a Significant Patent by USPTO for Methods of Treating Coronavirus Infection with Leronlimab
https://www.cytodyn.com/newsroom/press-releas...or-methods


2021.06.21 CytoDyn Inc. Announces Positive Preliminary Results of Unblinded Data from Long-Haulers Trial Showing Greater Improvement in Leronlimab Group over Placebo in 18 of 24 Symptoms
https://www.cytodyn.com/newsroom/press-releas...results-of

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
There are no guarantees in investing. No one should consider these pages or posts to be financial advice. Everyone has a responsibility to verify and thoroughly learn more than what is referenced or written here, and everyone must take responsibility for their own investing decisions.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Holiday Grease Advice Shows Utility Work Up Close Today

Updated Category News Views 117

Butter and pan drippings are mundane right until they become a backed-up kitchen line on a crowded holiday afternoon. New Jersey American Water's Nov. 17, 2026 reminder is not glamorous utility news, and frankly it is not trying to be. It is a practical warning: fats, oils and grease can cool, harden and accumulate in household pipes and farther along the wastewater...

Continue Reading
Azazie Tests Bridal Demand With Two East Coast Pop-Ups

Updated Category News Views 116

Wedding dresses are a miserable product to buy sight unseen, no matter how pretty the product photos look. That basic fact is why Azazie’s two East Coast pop-ups on November 21 and 22 deserve a closer look. This is not some grand retail rollout, and nobody should pretend a pair of short events rewrites the bridal market. But it is a practical test of where a...

Continue Reading
LifeVac's 7,000 Reported Saves Deserve Careful Context

Updated Category News Views 138

Veggie straws are supposed to be harmless until they are not. LifeVac says a 19-month-old girl in South Dakota became unable to breathe on November 14 after eating the snack, with a sticky piece creating a complete airway obstruction. Her father retrieved the family's LifeVac, used the pediatric mask while she was on her back, and the company says one application...

Continue Reading
Workday’s EU Cloud Move Raises the Sovereignty Bar Again

Updated Category News Views 19

Europe’s sovereignty squeeze just got a lot more concrete for Workday. The company is taking its EU Sovereign Cloud beyond the usual data-residency talking points by planning an Ireland-based operating company, European leadership, and governance intended to keep decisions on the service and customer data inside Europe. For a platform sitting underneath payroll, HR...

Continue Reading
Scalefusion’s Platinum Win Sharpens Its Brand Story

Updated Category News Views 14

A Film Is Not a Balance Sheet A slick brand film cannot patch a leaky product, but it can make a complicated platform easier to remember. That is the sensible takeaway from Scalefusion’s Platinum Level win at the 2026 MarCom Awards for “One Platform. One Agent. We are Scalefusion.” The recognition is for creative execution, not commercial performance, and anybody...

Continue Reading
Stand Out For Good Makes a Bold Michigan Avenue Bet

Updated Category News Views 183

A six-floor retail commitment lands with a thud Stand Out For Good is taking on roughly 51,079 square feet at 669 North Michigan Avenue, and nobody should mistake that for a casual expansion. Six levels on Chicago's Magnificent Mile is a proper declaration of intent, especially in a retail district that has endured plenty of empty-window handwringing and big-brand churn....

Continue Reading
Diwali at Heritage Shows the Real Estate Community Test

Updated Category News Views 89

Fireworks do not sell a townhome by themselves, but belonging can sure help close the distance between a brochure and a serious purchase. Heritage at South Brunswick recently held a Diwali celebration sponsored by American Properties at South Brunswick LLC, bringing homeowners, families, and the builder's team into the same room for an evening of food, music, dancing,...

Continue Reading
Abacus Global Faces Scrutiny Over Accounting Practices

Updated Category News Views 176

Storm Clouds Gather over Abacus Global Management If it ain't one thing, it's another—at least that's what folks holding the bag with Abacus Global (ABX) are thinking right now. News of a pending investigation has dropped like a lead balloon, and the air is thick with scrutiny over their financial dealings. We're jawing about related-party transactions now under the...

Continue Reading
Navan’s Travel Survey Sells Friction as a Business Case

Updated Category News Views 154

A forgotten charger can turn a routine trip into a small mutiny. That is the useful little truth sitting underneath Navan’s new survey of 2,000 Americans who travel for leisure or business. The company is poking at the annoyances people carry from the bedroom packing pile to the jet bridge: forgotten items, rushed airport arrivals, pre-flight drinks, chatty strangers,...

Continue Reading
Stitch AI Targets Banking’s Hardest Automation Gap

Updated Category News Views 15

The flashy chatbot stuff is cheap; banking permission to act is not. That is why Stitch AI’s launch deserves more attention than another vendor slapping “agentic” on a slide deck and calling it transformation. Banks do not need a machine to summarize a policy document while everyone applauds the demo. They need technology that can touch real workflows without...

Continue Reading

Top 5 Most Recently Viewed Articles

Broad Arrow to Showcase Exclusive BMW Cars in Italy Auction

Updated Category News Views 225

Broad Arrow Auctions Presents Exclusive BMW Event Broad Arrow Auctions is gearing up for an incredible showcase this May, as it proudly partners with the acclaimed Concorso d’Eleganza Villa d’Este. This prestigious event will feature a special BMW-only sale, spotlighting the rich history and legacy of the famed automobile brand. The auction takes place on May 24th and...

Continue Reading
Business Leadership Showcased in The Enterprise World's Newest Editions

Updated Category News Views 177

In 2024, The Enterprise World made waves by showcasing a lineup of remarkable business leaders. Traders and executives alike were keeping an eye on this publication as it spotlighted key figures in the B2B landscape, delivering insights that could very well influence investment decisions. Spotlight on Business Leadership: Who's Leading the Charge? This edition featured...

Continue Reading
How Elon Musk's Market Predictions Missed the Mark

Updated Category News Views 432

In recent times, the financial landscape saw the S&P 500 index rocket by nearly 50%, showcasing unexpected resilience. Traders had their eyes glued to this upward trend as it contradicted earlier predictions of an imminent market crash echoing the catastrophic events of 1929. Musk’s Dark Predictions: A Market Response? Elon Musk, the outspoken CEO of Tesla and SpaceX,...

Continue Reading
ScottsMiracle-Gro Sets Date for Q2 Financial Results Release

Updated Category News Views 229

Overview of ScottsMiracle-Gro's Upcoming Financial Results ScottsMiracle-Gro Company (NYSE: SMG), a prominent player in the lawn and garden industry, is gearing up to release its financial results for the second quarter. This anticipated announcement will take place on a day when U.S. financial markets are active, providing investors and stakeholders with insights into...

Continue Reading
Exploring the Dynamics of the S&P 500 in 2026

Updated Category News Views 257

Understanding the Market Landscape for 2026 As we gaze into the near future, a mixture of economic indicators and market trends is shaping the outlook for 2026. Analysts suggest that a strong year for the S&P 500 may be on the horizon. Historically, the absence of a recession fosters a fertile environment for stock gains, positioning equities well for investor...

Continue Reading